TrialThe oncologist2017

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Xiaofei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.